Portfolio company
HAYA Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
HAYA Therapeutics develops precision RNA therapies targeting long non-coding RNAs for patients with cardiovascular, metabolic, and age-related fibrotic diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cardior
This company develops RNA-based therapeutics designed to prevent, repair and reverse heart diseases for patients with cardiac dysfunctions.
Noara Therapeutics
This company engineers stable and immunosilent ribonucleic acid therapies using machine intelligence to treat patients with chronic and complex diseases.
Airna
This company develops RNA editing therapeutics to treat patients with rare genetic and common cardiometabolic diseases.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
BioAge Labs
This company develops therapeutic drugs targeting the biology of human aging to treat patients with metabolic and cardiovascular diseases.
ScionxBio
This biotechnology company develops long-acting RNA medicines for pharmaceutical partners and patients with cardio-metabolic diseases.
Resalis Therapeutics
This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.